Abstract

Purpose : The purpose of this study was to evaluate our treatment results of anal cancer. Methods and Materials : During the years 1985–1990, 82 patients with invasive epidermoid anal cancer were referred to the Department of Oncology at Sd̈ersjukhuset. In 76 cases irradiation was used in the primary therapy, and in 43 cases bleomycin was administered concurrently. Fifteen of these tumors were situated in the perianus and 61 in the anal canal. Probability of survival, recurrence, and preservation of anal sphicter was analyzed according to Kaplan-Meier. Cox multivariate analysis was used in studying potential determinants of risk for treatment failure. Results : Tumor-specific survival at 5 years was 71% for both anal canal and perianal cancer. Analyses with regard to cancer of the anal canal indicated that T4 tumors had significantly worse prognosis than those in stages TI-3. Overall survival was 73% and 79% at 5 years for T1 and T2 tumors and 73% and 18% at 4 years for T3 and T4 tumors. Corresponding figures for tumor specific survival were 79%, 79%, 82%, and 31%. Eighty-five precent of patients with T1 tumors, has a preserved anal sphincter after 4 years. For T2 and T3 tumors the corresponding figures were 62% and 60%. Also the multivariate analyses showed t$ to be a strong negative prognostic determinant. There was no firm evidence of a positive effect of bleomycin on the treatment results, but it increased the acute radiation toxicity. Conclusion : Primary radiotherapy of anal cancer yielded a high probability of survival, but in many cases sphincter amputation have been necessary. The role of bleomycin appears questionable.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.